The test MRSA and MSSA directly from blood culture samples in about one hour, compared to between 48 and 72 hours with other methods, the company said.
To develop the test, the firm said it used a library of MRSA strains collected around the world, and included components that reduce false positive results.
In Genome Biology this week: over-representation of European individuals in large datasets, methicillin-resistant Staphylococcus aureus clone in East Asia, and more.
The company attributed the increase in revenue to a $700,000 increase in product sales, particularly its rapid pathogen ID molecular diagnostic.
Researchers examined virulence, resistance, and transmission patterns in genome sequence data for more than 300 invasive Staphylococcus aureus isolates from Europe.
The upgraded test includes new gene targets for methicillin resistance, and provides room-temperature storage and validation on multiple swab types.
The approach allows more rapid detection of resistant strains as well as detection of certain populations for which good clinical assays don't currently exist.
The technology is being used to analyze pathogen samples in a clinical study examining methods to combat recurrent drug-resistant Staph infections.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
If approved, the multiplex Staph panel will grow the firm's menu of assays on its molecular platform to three.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.
Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.
Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.